NCT05919264 2026-04-09FOG-001 in Locally Advanced or Metastatic Solid TumorsParabilis Medicines, Inc.Phase 1/2 Recruiting595 enrolled
NCT06607185 2026-03-13A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsEli Lilly and CompanyPhase 1 Active not recruiting750 enrolled
NCT03314935 2025-08-12A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid TumorsIncyte CorporationPhase 1/2 Completed149 enrolled 35 charts
NCT03872947 2025-08-03A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid TumorsToray Industries, IncPhase 1 Active not recruiting138 enrolled
NCT03197584 2025-02-21QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) TherapyImmunityBio, Inc.Phase 1/2 Withdrawn
NCT02658214 2020-08-20Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid TumorsAstraZenecaPhase 1 Completed32 enrolled
NCT03011320 2019-02-07An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing SurgeryEndocytePhase 1 Completed3 enrolled
NCT00782041 2009-09-15Patients Who Have Failed First Line Treatment for Locally Advanced and/or Metastatic Cervical CancerSanofiPhase 2 Terminated11 enrolled